Gujarat Themis Biosyn's quarterly market cap
increased
from Sep. 2025 (₹43,265 Mil) to Dec. 2025 (₹48,212 Mil) but then
declined
from Dec. 2025 (₹48,212 Mil) to Mar. 2026 (₹24,784 Mil).
Gujarat Themis Biosyn's annual market cap
increased
from Mar. 2024 (₹28,774 Mil) to Mar. 2025 (₹30,674 Mil) but then
declined
from Mar. 2025 (₹30,674 Mil) to Mar. 2026 (₹24,784 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Gujarat Themis Biosyn's Enterprise Value for Today is ₹42,852 Mil.
Gujarat Themis Biosyn (BOM:506879) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Themis Biosyn's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Themis Biosyn Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gujarat Themis Biosyn's Market Cap distribution charts can be found below:
* The bar in red indicates where Gujarat Themis Biosyn's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Gujarat Themis Biosyn's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Themis Biosyn (BOM:506879) has a Market Cap of ₹41,298 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Gujarat Themis Biosyn and its competitors. According to the industry distribution chart, Gujarat Themis Biosyn ranks #416 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Gujarat Themis Biosyn's Market Cap too high?
Gujarat Themis Biosyn's current Market Cap is ₹41,298 Mil. Based on the distribution chart, Gujarat Themis Biosyn ranks #416 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gujarat Themis Biosyn has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Themis Biosyn's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gujarat Themis Biosyn ranks #416 out of 1024 companies for Market Cap. This puts Gujarat Themis Biosyn in the upper half of its industry. The industry median Market Cap is 214.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 214.09, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Gujarat Themis Biosyn and its competitors. For the Drug Manufacturers industry, the median Market Cap is 214.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Themis Biosyn's current Market Cap is ₹41,298 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Themis Biosyn stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Themis Biosyn (BOM:506879) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹313.28, compared to a current price of ₹379.00 — trading 21% above its estimated fair value. The current Market Cap is ₹41,298 Mil. Gujarat Themis Biosyn's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Gujarat Themis Biosyn (BOM:506879), the current Market Cap is ₹41,298 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gujarat Themis Biosyn (BOM:506879) Overvalued in 2026?
Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued.
The current stock price of ₹379.00 is trading 21% above its estimated GF Value™ of ₹313.28.
GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.
Key valuation signals for BOM:506879:
Market Cap: ₹41,298 Mil
GF Value™: ₹313.28 vs. price of ₹379.00 (21% above fair value)
No single metric tells the full story. See the BOM:506879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
75GF Score
Get the complete analysis for BOM:506879
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506879 has been successfully added to your 
